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Abstract 
Bluetongue disease is caused by bluetongue virus (BTV) and BTV serotype 8 (BTV8) caused great economic damage 
in Europe during the last decade. From 1998 to 2007, in addition to BTV8, Europe had to face the emergence of BTV1, 
2, 4, 9, and 16, spreading in countries where the virus has never been detected before. These unprecedented out-
breaks trigger the need to evaluate and compare the clinical, virological and serological features of the European BTV 
serotypes in the local epidemiological context. In this study groups of calves were infected with one of the following 
European BTV serotypes, namely BTV1, 2, 4, 9 and 16. For each tested serotype, two groups of three male Holstein 
calves were used: one group vaccinated against BTV8, the other non-vaccinated. Clinical signs were quantified, viral 
RNA was detected in blood and organs and serological relationship was assessed. Calves were euthanized 35 days 
post-infection and necropsied. Most of the infected animals showed mild clinical signs. A partial serological cross 
reactivity has been reported between BTV8 and BTV4, and between BTV1 and BTV8. BTV2 and BTV4 viral RNA only 
reached low levels in blood, when compared to other serotypes, whereas in vitro growth assays could not highlight 
significant differences. Altogether the results of this study support the hypothesis of higher adaptation of some BTV 
strains to specific hosts, in this case calves. Furthermore, cross-protection resulting from a prior vaccination with BTV8 
was highlighted based on cross-neutralization. However, the development of neutralizing antibodies is probably not 
totally explaining the mild protection induced by the heterologous vaccination.
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(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Bluetongue virus (BTV) represents the type species 
of the Orbivirus genus, family Reoviridae and causes 
bluetongue disease (BT) in susceptible species [1, 2]. 
BTV is usually transmitted to domestic and wild rumi-
nants by the bite of haematophagous female midges of 
the Culicoides genus yet direct transmission was dem-
onstrated at least for serotype 26 [3]. From 1998 to 
2006, Europe had to face an unprecedented emergence 
of BTV serotypes 1, 2, 4, 9 and 16 (BTV1, 2, 4, 9, 16) 
throughout the Mediterranean Basin, including several 
countries where the virus was never detected before. 
August 2006 is a tipping point in BTV epidemiology, 
with a first detection of BTV8 in Europe Mainland [4] 
and a subsequent wide spread throughout Europe dur-
ing the following 2  years. BTV8 emergence was easily 
spread through Culicoides species that were not known 
as the historic BTV transmission species, i.e. Culicoides 
obsoletus complex species [5]. This epidemic—affecting 
abundantly cattle whereas previous outbreaks largely 
occurred in small ruminants—is considered to have 
caused greater economic damage than any previous 
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single serotype outbreak [6]. Most of the countries 
involved in the beginning of the BTV8 epidemic and 
that paid the heaviest toll were declared bluetongue-
free in 2012 (Belgium, the Netherlands, Germany, 
France [7, 8]).
Bluetongue virus virulence and transmission potential 
is not serotype driven thus outcome of the infection can-
not be predicted based on the serotype alone [9]. Within 
a serotype, the geographical origin can be used to define 
topotypes with different pathogenicity. As an example, 
some Australian strains were reported to be less viru-
lent than their Western counterparts [10]. The presence 
of competent palearctic vectors and several serotypes 
recently described in Europe mainland, with non-immu-
nized livestock, trigger the need to evaluate and com-
pare the clinical, viral and immunological features of the 
European BTV serotypes in cattle. In addition, since the 
European BTV8 showed an unusual virulence in cattle, 
the emergence of another serotype could take place in an 
area with local cattle possibly already immunized against 
BTV8.
Serological relationships between the different BTV 
serotypes were mostly established more than 25  years 
ago based on plaque reduction tests and cross-protec-
tion experiments in sheep [11]. It is assumed that there 
is partial or no cross-protection between the differ-
ent BTV serotypes, therefore the need of serotype spe-
cific vaccination strategies. At the moment, a total of 27 
serotypes have been recorded [12], possibly 29 [13]. As 
a consequence, developing and implementing multi-
serotype prophylactic approaches to tackle BTV is one of 
the major challenges in the control of the disease. Cross-
reactivity between BTV1 and BTV23 [14], BTV1 and 
BTV8 [15] or more recently between BTV16 and mul-
tivalent serum of sheep vaccinated against BTV9, 2 and 
4 [16] was reported. These serotypes are however tradi-
tionally considered as poorly related.
The current study was implemented to pursue two 
main objectives. First, to assess and compare the viru-
lence of some of the BTV serotypes threatening Europe 
mainland—namely BTV1, BTV2, BTV4, BTV9 and 
BTV16—in controlled conditions in calves. Second, 
to evaluate the extent of cross-protection granted by 
BTV8 vaccination in calves infected with these sero-
types. In addition, in  vitro humoral cross-reactivity was 
determined.
To these ends, each of the tested serotypes (BTV1, 
BTV2, BTV4, BTV9, and BTV16) was used to infect 
two groups of calves. One group was vaccinated against 
BTV8 using a commercial inactivated vaccine, and the 
other group was not. The clinical, pathological and viro-
logical consequences of the infection with these differ-
ent serotypes, whether the animals were vaccinated or 




Animals were treated in accordance with the Inter-
national Guiding Principles for Biomedical Research 
Involving Animals, as issued by the Council for the 
International Organizations of Medical Sciences and EU 
Directive 2010/63/EU for animal experiments.
A total of 35 Holstein male calves, about 5.5–6 months 
old, were used. All the selected animals were tested 
seronegative (ELISA and seroneutralization) and non 
viraemic (RTqPCR) for BTV and Bovine herpesvirus 1 
(BoHV1). In addition these calves were also born from 
BTV naïve dams (seronegative and RTqPCR negative). 
They were introduced in an insect secured BSL3 facility 
1 week before the beginning of the experiment to allow 
their acclimatization.
Virus
BTV1, BTV2, BTV4, BTV9 and BTV16 were all derived 
from the reference strains of the Onderstepoort Veteri-
nary Institute. These strains underwent further passages 
at The Pirbright Institute (TPI); passage history is avail-
able at the RNAs and Proteins of dsRNA Viruses [17]. 
The BTVs were subsequently passaged at Sciensano, 
Ukkel, Belgium (formerly CODA–CERVA) between two 
and four times on BHK-21 cells. BTV8 originated from a 
field sample (BEL2006/01) afterwards passaged 6 times in 
BHK-21. Each serotype has been tested by RTqPCR spe-
cific of the serotypes used in the study to rule out poten-
tial contamination of the inocula.
Experimental design
Five animals were kept as environmental control, and 
were inoculated with Dulbecco’s Modified Eagle Medium 
(DMEM, Life Technologies, Gent, Belgium). Groups 
were identified by their vaccination status against BTV8 
(V_ or NV_, respectively vaccinated and non-vaccinated) 
followed by the subsequently inoculated BTV serotype 
(BTV1, BTV2, BTV4, BTV9 or BTV16). For each tested 
serotype, two groups of three calves each were used. The 
animals from the first group were vaccinated against 
BTV8 (BTVPUR AlSap 8, Merial, Lyon, France) follow-
ing manufacturer instructions, with the second vaccine 
injection 33 days before challenge. In the other group the 
animals were not vaccinated.
To be infected, the animals received between 2.5 and 
4 mL of inoculum, properly diluted to a normalized titre 
of  106  TCID50/animal. Inoculations were realised through 
the subcutaneous route, on the left side of the neck. Daily 
examination of the calves included temperature and 
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clinical signs monitoring for 35 days post-infection (dpi). 
The severity of the infection was quantified by calculat-
ing clinical scores per system and per animal, leading to 
overall clinical scores by groups and animal, following a 
standardised clinical form adapted from Saegerman et al. 
[18]. Briefly, clinical signs were summed up according to 
their nature (general signs versus localised clinical signs 
on muzzle, mouth, limbs and eyes) and intensity (crust, 
ulcerations or necrosis, oedema or inflammation). The 
calves were euthanatized at 35 dpi by captive bolt stun-
ning followed by bleeding. Extensive necropsy has been 
performed, and spleen, thymus, prescapular and mes-
enteric lymph nodes, testicle and lung were sampled 
from infected and control calves, to detect BTV RNA by 
RTqPCR.
BTV RNA detection
Viral RNA extraction from the blood was achieved using 
the QIAamp Viral RNA Mini Kit (Qiagen, Antwerp, Bel-
gium). In the organs, about 100 mg of tissues per organ 
were processed; viral RNA extraction was performed 
using Trizol reagent according to the manufacturer’s 
instructions (Gibco Invitrogen, UK). Viral RNA denatur-
ation and reverse transcription were adapted from previ-
ously published protocols [19] with slight modifications, 
as denaturation was realised in presence of random hex-
amers. Serotype specific RTqPCR assays were carried out 
for BTV1, BTV2, BTV4, BTV8, BTV9 and BTV16 using 
LSI VetMAX European BTV Typing Real-Time PCR 
Kits (ThermoFisher Scientific, Gent, Belgium), following 
manufacturer’s instructions.
RTqPCR reactions were run on a CFX96 Touch™ Real-
Time PCR Detection System (Bio-Rad Laboratories N.V., 
Temse, Belgium) using the following cycling conditions: 
heat inactivation at 95 °C for 10 min, 50 cycles consisting 
of denaturation at 95  °C for 15  s and annealing/elonga-
tion at 58 °C for 30 s.
To allow absolute quantification of the viral RNA con-
tent in blood and organ samples, standard curves of sero-
type specific plasmids  (pGEM®-T Easy Vector, Promega, 
The Netherlands), carrying the target part of the segment 
2, were constructed. Quantification was expressed in 
cDNA copy number/mL of blood.
Anti‑BTV antibodies detection
For each tested serotype neutralizing antibodies (Abs) 
were titrated by seroneutralization (SNT). Two-fold serial 
dilutions of the sera (1:10–1:1280) were tested in the 
presence of 100  TCID50 of BTV, as previously described 
[20]. The neutralizing antibody titre was defined as the 
reciprocal of the serum dilution causing a 50% reduction 
in cytopathic effect. Serum of all the animals has been 
tested at several time points with the homologous virus.
Anti-VP7 antibodies circulation was also evaluated 
using a commercial competitive ELISA kit (ID  Screen® 
Bluetongue Competition ELISA kit, ID Vet, France). 
Results were expressed as % negativity (PN) compared 
to the negative kit control and transferred to a positive, 
doubtful or negative result according to the cut-off set-
tings provided by the manufacturer (PN ≤ 35 is positive; 
35 < PN ≤ 45 is doubtful; PN > 45 is negative). As these 
cut-off values were rather designed for screening pur-
poses [21], the cut-off suggested by Vandenbussche et al. 
[19] (negative when PN > 66) has been also considered as 
a tool for individual diagnostic, with respect of the lim-
ited number of animals.
Haematology
Starting during the acclimatization period and until the 
end of the experiment, a complete haemogram (Vet ABC, 
SCIL animal care company, France), including total leu-
kocytes, monocytes, lymphocytes, neutrophils, eosino-
phils and basophils was performed on EDTA blood 
samples on a regular basis.
Cross‑neutralization assay
In each non-vaccinated group, the individual serum sam-
ple with the highest homologous neutralizing titre has 
been selected and subsequently tested by SNT against 
all the other inoculated BTV serotypes. In order to avoid 
potential bias due to low humoral response against any 
of the serotype, heterologous neutralization results for 
each tested serotypes were expressed as a percentage of 
the titre reached when the immunised serum was tested 
with the homologous serotype. BTV8 immune serum 
was obtained from an experimentally infected heifer in a 
previous study [22].
In vitro kinetic growth of BTV serotypes
In vitro growth properties of the 6 BTV serotypes (i.e. 
BTV1, BTV2, BTV4, BTV8, BTV9 and BTV16) used in 
this study were compared using their replication kinet-
ics in VERO cell culture, following a protocol adapted 
from Dal Pozzo et  al. [23]. Briefly, all the inocula were 
used in a one-step growth assay, with confluent VERO 
cells, at a multiplicity of infection (m.o.i.) of 0.05. After 
0, 8, 24, 48, 72, 96 and 120 h incubation, the supernatant 
was removed and stored −80 °C. For each time point, the 
virus titre was determined at least in triplicate by plaque 
assay [24] and expressed as Log  TCID50/mL.
Infectivity
For each serotype, the original inoculum plus two serial 
1:10 dilutions were tested by RTqPCR. Knowing the 
infectious titre of each inoculum, for each serotype a 
mean ratio of segment 2 (S2) cDNA/TCID50 was then 
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calculated. The infectious titre of the blood samples was 
then extrapolated using RTqPCR results multiplied by 
the mean segment 2 cDNA/TCID50 ratio and expressed 
as  TCID50/mL, for each tested time points.  TCID50/mL 
titres were then converted in PFU/mL to assess the level 
of infectivity of each serotype based on the estimate of 
the minimal PFU/mL required to infect vector Culicoides 
according to Dungu et al. [25].
Statistical analysis
For viraemia levels and infectivity assessment between 
vaccinated and non-vaccinated groups, the compari-
son of quantitative parameters was performed using 
pair-wise t tests or Welch test, as appropriate. One-way 
ANOVA with post hoc Tukey test were used to ana-
lyse haematological values within the same group with 
respect to baseline values at 0 dpi. Differences between 
control and infected groups at the same time-point were 
analyzed using a two-way mixed model ANOVA with 
Bonferroni post-test. Two-way mixed model ANOVA 
were calculated using the statistical analysis program 
GraphPad Prism version 5.01 for Windows (GraphPad 
Software, San Diego California USA). Other statistical 
analyses were realized using the R software/environment 
(R-3.2.1, R Foundation for Statistical Computing). For all 
tests, P values < 0.05 were considered significant.
Results
Clinical examination
Two calves from the control group showed 1–2 days-lasting 
hyperthermia between 6 and 12 dpi, without other systemic 
problem or clinical signs evocative of bluetongue disease. In 
infected animals, clinical signs were mild, and would prob-
ably go unnoticed in the field, as appetite was conserved 
and general condition unchanged. Nevertheless, typical 
bluetongue clinical signs were observed, including facial 
oedema, swelling and reddening of the odontoid papillae, 
crusts and erosions at the muco-cutaneous junction, nasal 
discharge and purulent conjunctivitis. V_BTV9 group and 
NV_BTV1 group clinical scores were significantly higher 
than control group (P < 0.05). V_BTV9 and NV_BTV16 
groups had a significantly higher clinical score than their 
counterparts infected with the same serotype but different 
vaccination status. There were no significant differences 
between clinical scores of other infected groups when com-
pared to each other, to the control group or when comparing 
groups infected with the same serotype but with different 
vaccination status (Figure  1). A great individual variability 
was observed in the clinical outcomes within each group, as 
in 6 out of 10 infected groups, one single animal totalized 
50% or more of the total clinical score of the group.
BTV RNA detection
No viral RNA was detected in any of the control ani-
mals at any time point. Inoculated animals showed dif-
ferent viraemia patterns depending on the inoculated 
serotype and their vaccination status. The earliest BTV 
RNA detection in the blood occurred at 1 dpi in NV_ and 
V_BTV1 groups. The latest onset of viraemia occurred in 
one calf of V_BTV2 group at 11 dpi. In calves infected 
with serotypes 2 and 4 BTV RNA could only be detected 
inconsistently and RNAemia reached moderate levels 
when compared to calves infected with BTV1, 9 and 16 
(Figure 2). After the challenge of vaccinated animals, the 
Log copy number of viral RNA was significantly lower in 
BTV2 and BTV4 groups when compared to BTV9 and 
BTV16 groups (Two way ANOVA with repeated meas-
ures, P < 0.004). In addition, BTV1 RNA detection was 
also significantly lower than BTV9 (P < 0.013). After the 
challenge of non-vaccinated animals viral RNA detec-
tion was significantly lower in BTV2 and BTV4 groups 
when compared with BTV9 and BTV1 groups (P < 0.003), 
and BTV4 RNA detection was significantly lower than 
BTV16 (P < 0.005). Regarding homologous serotypes, 
only BTV1 showed a lower RNA detection in V group 
versus NV group (P < 0.016). Vaccinated animals had an 
RNAemia ranging from 79.4 to 95.5% of the max RNAe-
mia level of the non-vaccinated animals at the viraemic 
peak. At the end of the experiment viral RNA was still 
detectable in 40% of the vaccinated animals versus 73% in 
the non-vaccinated calves. However this difference was 
not significant (χ2, P = 0.065).
Figure 1 Total clinical scores by group and vaccination status. 
Error bars represent standard error of the mean. *P < 0.05 between 
vaccinated and non-vaccinated groups infected with the same 
serotype. #P < 0.05 compared to the control group.
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Figure 2 Individual daily viral genome load in calves’ blood. Results are expressed as the Log copies of BTV segment 2 cDNA per mL of blood. 
A and B BTV1; C and D BTV2; E and F BTV4; G and H BTV9; I and J BTV16. C, E, G and I are non-vaccinated groups whereas B, D, F, H and J are 
vaccinated groups; dpi: day post-infection.
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Anti‑BTV antibodies detection
All the inoculated animals produced homologous 
neutralizing antibodies that started generally to be 
detected two to 3  weeks post-infection (Figure  3). In 
previously BTV8 vaccinated calves, the rise of neutral-
izing antibodies against the virus serotype used in the 
challenge was earlier detected and reached higher lev-
els compared to non-vaccinated calves however only 
significant for BTV2 infected animals (P < 0.035). In 
vaccinated animals, anti-BTV8 neutralizing antibod-
ies were contemporaneously circulating (Figures 3B–J) 
and anti-BTV8 titres were significantly higher than in 
NV animals for all serotypes. Whereas no significant 
increase in anti-BTV8 neutralizing antibodies could be 
detected in non-vaccinated animals, vaccinated ones 
from groups inoculated with BTV2 and 16 underwent a 
slight boost in anti-BTV8 neutralizing antibodies titres, 
despite the heterologous nature of inoculated serotype 
(P < 0.006).
Neutralizing antibodies titres had no correlation with 
viral RNA detection level (r = 0.12, P = 0.11) and maxi-
mal SNT titres had no correlation with maximal BTV 
RNA copy number (r = 0.09, P = 0.63).
The cELISA kit managed to detect Anti-VP7 antibod-
ies for each tested serotype. The time of seroconversion 
was in line with previously published data [20, 26, 27], 
between 10 and 21 dpi for all serotypes (Figure  4). By 
the time of inoculation, 2 V_BTV2 and 2 V_BTV4 calves 
had a PN above the positivity threshold (thus considered 
negative) determined by the manufacturer (PN ≤ 35), 
however considered positive if taking into account of the 
threshold defined by Vandenbussche et al. [19] (PN ≤ 66). 
All these 4 animals had PN that reached values under 35 
within 7 dpi.
Haematology
Monocyte counts increased shortly after infection in all 
groups but control animals independently of their vacci-
nation status. The increase started between 4 and 11 dpi, 
peaked at 15 or 18 dpi and then came back to baseline 
levels by 35 dpi (Figure 5). All NV groups showed peaks 
significantly higher than baseline value (0 dpi) or control 
value at the same time point (Figure 5A, P < 0.05, two way 
ANOVA with repeated measures) whereas in V groups 
only peaks of V_BTV1, BTV2, and BTV9 were signifi-
cantly higher (Figure 5B, P < 0.05, two way ANOVA with 
repeated measures).
Lymphocyte count followed a different trend, decreas-
ing in the first dpi, from about 4–11 dpi, then recover-
ing and even significantly exceeding baseline values 
(Figure  5D, V_BTV4: 18 dpi, P < 0.05, two way ANOVA 
with repeated measures) or control values at the same 
time point (Figures 5C and D, NV_BTV2: 25 dpi and V_
BTV16: 21, 25 and 35 dpi, P < 0.05, two way ANOVA with 
repeated measures).
Necropsy and BTV RNA detection in organs
At the necropsy, lesions were sporadically reported, 
including haemorrhage and petechial haemorrhage on 
several lymph nodes, endocardic suffusion, abscesses and 
petechial haemorrhage in the lung, and a slight haemor-
rhage in the wall of the pulmonary artery of one calf in 
the NV_BTV9 group.
No viral RNA could be detected in any organs of the 
animals of the BTV2 and BTV4 groups, whether they 
were vaccinated or not (Table 1). The proportion of posi-
tive organs was significantly higher in BTV9 infected 
groups (pairwise Fisher test, P < 0.002). However there 
was no significant difference between BTV9  V and NV 
groups regarding organ detection (P = 0.075). Consider-
ing all serotypes all together, viral RNA was most com-
monly detected in prescapular lymph node (Table  1). 
In vaccinated animals infected with BTV9, detection of 
BTV RNA in organs was associated with an Odds Ratio 
of 0.16 (P < 0.03, [0.029–0.691]).
Cross neutralization assay
Different degrees of in  vitro cross neutralization could 
be found using all immunized sera (Table  2). However, 
immunized sera of BTV2 and BTV9 showed the least 
degree of in  vitro cross neutralization against the other 
tested viral serotypes. On the contrary, BTV8 immune 
serum had a higher neutralization effect in  vitro on the 
growth of BTV4, reaching a titre equal to 25% against 
BTV4 when compared to the titre reached against BTV8 
itself. BTV1 immune serum reached a similar level of 
partial seroneutralization against BTV8. A lesser cross 
neutralization has been reported with the BTV16 serum 
towards BTV1 virus (Table 2).
In vitro kinetic growth of BTV serotypes
The mean virus titres measured for each serotype at the 
different time points were compared to all the other sero-
types using a two-factor ANOVA with repeated measures 
on one factor, showing no significant difference between 
the different kinetic growth curves (P = 0.41, Figure 6).
BTV1, 2, 6 and 16 had earlier replication as cytopathic 
effect (CPE) has been reported since 8  h post-infection 
(hpi), whereas BTV4, 8 and 9 showed CPE starting at 24 
hpi.
Infectivity
At viraemic peak S2 copies number ranged from 
 106.52 (± 0.73) for NV_BTV9 to  103.39 (± 1) for NV_BTV4 
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Figure 3 Evolution of neutralising antibodies titres against BTV8 and homologous inoculated serotypes. A, C, E, G and I (full lines): mean 
neutralising antibodies titres per group against respectively BTV1, 2, 4, 9 and 16. In each panel vaccinated (triangle) and non-vaccinated (filled circle) 
groups are represented. B, D, F, H, J (dashed lines): mean neutralising antibodies titres against BTV8 in vaccinated (triangle) and non-vaccinated 
(filled circle) animals in respectively BTV1, 2, 4, 9 and 16 inoculated groups. Error bars represent standard error of the mean. dpi: day post-infection.
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Figure 4 Evolution of serogroup specific antibodies. The results are presented for each animal as the percentage of negativity (PN) obtained 
in the competitive ELISA. Data for non-vaccinated (filled circle) and vaccinated (triangle) animals are shown for BTV1 (A, B), BTV2 (C, D), BTV4 (E, F), 
BTV9 (G, H) and BTV16 (I, J). Dotted line represents the cut-off value recommended by the manufacturer and dashed line the one suggested by 
Vandenbussche et al. [18]. dpi: day post-infection.
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Figure 5 Lymphocytes and monocytes cell counts. Mean monocytes (A and B) and lymphocytes (C and D) cell counts in non-vaccinated (A 
and C) and vaccinated animals (B and D), expressed as  109 cells/L. dpi: day post-infection. For a better readability error bars were removed. *P < 0.05; 
**P < 0.01 and ***P < 0.001 between vaccinated and non-vaccinated groups infected with the same serotype. #P < 0.05; ##P < 0.01; ###P < 0.001 
compared to the control group.
Table 1 BTV RNA detection in organs at necropsy 
Results are expressed a BTV RNA copy number per 100 mg of tissue.
No positive detection could be found in any tested sample in BTV2 and BTV4 vaccinated or non-vaccinated groups.
NV_: non vaccinated group; V_: vaccinated group; NEG: negative result; Mesent. LN: mesenteric lymph node; Prescap. LN: prescapular lymph node.
Calf ID Spleen Mesent. LN Prescap. LN Thymus Testicle Lung
NV_BTV1 169 NEG NEG 7.41 NEG NEG NEG
1004 NEG NEG 6.27 NEG 3.33 NEG
6712 NEG NEG 4.92 NEG NEG NEG
V_BTV1 2038 NEG NEG 0.40 NEG NEG NEG
2044 1.42 NEG 18.96 NEG NEG NEG
5093 NEG NEG NEG 0.15 NEG NEG
NV_BTV9 1058 NEG 4.73 57.43 28.61 2.23 0.57
2071 12.22 4.36 18.78 NEG 1.89 1.30
3045 2.00 1.14 5.72 0.52 4.59 NEG
V_BTV9 2740 NEG 7.40 NEG 24.48 1.71 NEG
3934 0.96 0.88 2.09 NEG NEG NEG
4935 11.84 NEG 9.46 NEG NEG NEG
NV_BTV16 5583 NEG NEG 2.25 NEG NEG NEG
8606 NEG NEG NEG NEG NEG NEG
9535 NEG 0.23 NEG 17.34 NEG NEG
V_BTV16 2461 NEG NEG NEG NEG NEG NEG
3150 NEG NEG NEG 97.22 NEG NEG
5077 NEG NEG 2.70 NEG NEG NEG
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(Figure  7A), which correspond to a titre of  103.74 (± 0.42) 
 TCID50/mL for NV_BTV9 group and  100.58 (± 0.11) 
 TCID50/mL for NV_BTV4 (Figure  7B). Only BTV9 and 
BTV16 groups had consistently max viraemia higher 
than  103155  TCID50/mL (threshold value under which 
oral infection of Culicoides is supposed to be impos-
sible according to Dungu et  al. [25]) in all animals. 
Amongst BTV1 infected calves only NV_BTV1 calf 0169 
had a max viraemia above the threshold. No animals in 
the BTV2 or BTV4 groups had a viraemia above  103155 
 TCID50/mL whichever was the considered time point or 
vaccination status.
Discussion
In this study BTV inoculation resulted from asympto-
matic affection to mild clinical signs. Although contro-
versial [20, 28, 29] the passage history of the virus used in 
the current study could influence the clinical expression 
of the disease. Individual susceptibility could be another 
explanation [1].
Unlike in many other viral diseases [30–32], it was 
not possible to demonstrate a statistically significant 
relation between level and duration of viraemia, and 
clinical presentation. However this is not surprising in 
BTV infection, as RNAemia lasts longer in cattle than 
in sheep despite the more severe outcome in the latter 
species [33]. Furthermore, BTV clinical picture in cattle 
is usually subtle and does not allow to make any corre-
lation with the viral RNA detection in the blood.
On the other hand, BTV replication level has been 
correlated to the adaptation of the virus to the host 
[34]. In this study and based on the levels of viral RNA 
detection serotypes were ranked as follows from the 
most to the less adapted in calves: BTV9, 1, 16, 2 and 4 
in non-vaccinated groups, and BTV9, 16, 1, 2 and 4 in 
vaccinated ones. The limited circulation of BTV2 and 
BTV4 RNA in blood might explain the absence of posi-
tive detection in organs at necropsy. The hereinabove 
suggested host adaptation ranking based on BTV sero-
types might involve non-serotype specific virulence 
factors, in line with findings from Caporale et al. [35].
For standardization purposes the same doses were 
inoculated, regardless of the serotype. It has to be 
stressed that different BTV strains or serotypes, as 
a consequence of their large variability, their origin, 
could indeed be non-equivalently adapted to their 
hosts. Dal Pozzo et al. described a dominance of BTV8 
in cattle when compared to BTV1 and BTV15 [23]; 
North American serotype 10 replicates more efficiently 
in sheep than serotype 17 [36], and comparing BTV1 
and BTV15, BTV1 seems to be better adapted to sheep 
whereas BTV15 is better adapted to cattle [34]. In addi-
tion, the modified live vaccine (MLV) required doses to 
grant protection in sheep have been determined to be 
different depending on the considered serotype [37]. 
Indeed the low replication level of BTV4 and BTV2 
observed in this study might rely on an inoculation 
Table 2 Percentages of relative homologous and heterologous seroneutralization titers 
Immunised serum BTV serotype
BTV1 BTV2 BTV4 BTV8 BTV9 BTV16
Control 0.52 1.11 0.55 0.44 0 3.54
BTV1 100 1.11 8.85 25 0 3.54
BTV2 1.3 100 3.15 0.44 0 3.54
BTV4 0.65 0.88 100 0.44 0 12.5
BTV8 10.36 12.5 25 100 6.25 3.54
BTV9 2.61 3.1 0.77 0.44 100 3.54
BTV16 18.34 12.39 0.83 0.44 0 100
Figure 6 In vitro kinetic growth of BTV1, 2, 4, 9, and 16. Growth 
curves of BTV1, 2, 4, 8, 9 and 16 in VERO cells. Cells were infected at a 
MOI of 0.05 and supernatant collected at 8, 24, 48, 72, 96 and 120 h 
post-infection (hpi). Then supernatants were titrated on VERO cells 
by end-point dilution assay and expressed as the Log  (TCID50/mL). 
Each growth curve has been established independently at least in 
triplicate for each serotype.
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dose insufficient for these serotypes and support the 
hypothesis of a poor adaptation to cattle.
Amongst the serotypes used in this study, Erasmus 
described serolological relationship, based on cross-
protection tests in sheep or heterotypic antibody 
responses, between serotypes 2 and 1, 1 and 9, and 9 
and 4; serotypes 8 and 16 being quite serologically 
isolated [11]. In the current study cross neutraliza-
tion tests revealed moderated antigenic relationships 
mainly between serotypes 4 and 8, 1 and 8 and to a 
lesser extent 2 and 9. Partial cross neutralization has 
been previously reported between serotypes 1 and 8 
[15]. The discrepancies among the above mentioned 
studies have to be interpreted carefully, as the origin of 
the used isolates varies greatly, from African strains to 
European field isolates. In addition, the intra-serotype 
VP2 nucleotide sequence variation can be up to more 
than 30% [38]. The quasispecies nature of BTV, its evo-
lution through genetic drift and founder effect could 
explain the divergences between VP2 amino acids 
sequences and in vitro cross neutralization assays.
In this study the serological cross-reactivity with BTV8 
was limited to BTV4 and BTV1. Consequently, the dif-
ferences observed in the course of the current experi-
ment between vaccinated and non-vaccinated groups are 
most likely unrelated to humoral immunity. Numerous 
studies have described the importance of cell-mediated 
immunity in the course of BTV infection [14, 39]. Cell-
mediated immunity is suggested to rely to an important 
extent on non-structural proteins [40]. Despite non-
structural proteins not being part of the viral particles 
used to produce inactivated vaccines, vaccinated animals 
were reported to develop antibodies against NS proteins 
[41]. Therefore, in this study, the shorter RNAemia and 
lower BTV detection frequency in organs of the vacci-
nated animals might reflect a partial NS proteins based 
protection. In addition, VP7 peptides have also been 
shown to be recognized by CTL in natural host and are 
considered to share similar sequences for several BTV 
serotypes [42]. This might be one of the underlying 
mechanisms that could explain the partial cross-protec-
tion of BTV1 immunization against BTV23 challenge 
described by Umeshappa et al. [14]. This is not contradic-
tory to the findings of the present study, as BTV8 is as 
remotely related to the other European tested serotypes 
than BTV1 is related to BTV23, with respect to Erasmus 
description [11].
In our study no differences were observed among 
the haematology parameters measured after challenge 
among vaccinated and non-vaccinated groups. Mono-
cytosis starting from 4 dpi and can be directly linked 
to BTV infection which induces transcriptional activa-
tion of bovine monocyte-derived macrophages [43]. The 
increase of monocyte count in infected cattle might be 
part of the mechanisms explaining the moderate clini-
cal picture in bovine, by contrast to the severity of the 
disease in sheep [44]. Indeed, differences in BTV patho-
genesis in sheep and cattle were reported to be related to 
different production levels of vasoactive mediators [44]. 
Simultaneous in vivo experimental infection of cattle and 
sheep could be carried out along with a detailed charac-
terization of the cytokines produced in each species to 
clarify this hypothesis.
Figure 7 Mean S2 cDNA copy number and infectivity at viraemic peak. A S2 cDNA mean copy number at viraemic peak by tested serotype 
and vaccinated status. B Infectivity at viraemic peak, expressed as mean Log  TCID50/mL of blood titre by tested serotype and vaccinated status. 
Dotted line represents the classical threshold of  103155  TCID50/mL required to allow BTV transmission to vector Culicoides. *For NV_BTV4, one animal 
had no detectable viraemia at all was excluded from calculation. Error bars represent standard deviation.
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The minimum level of required viraemia to infect a 
vector has been established for several arthropod borne 
pathogens of major concern, like West Nile Virus [45], 
Dengue virus [46] or Chikungunya virus [47]. For BTV, 
MLVs are expected to lead to a viraemia lower than 
 103  PFU/mL, which is about  103155  TCID50/mL, sup-
posed to prevent oral infection of Culicoides [48], even if 
it has been clearly reported that many MLVs could give 
raise to higher titres in experimental conditions and pos-
sibly lead to MLV circulation in the field in Europe [49, 
50]. In the current experiment, only BTV9 and BTV16 
infection could reliably reproduce a viraemia above 
 103155  TCID50/mL at some points. It is however impor-
tant to stress that the putative  103155  TCID50/mL thresh-
old is largely discussed and remains debatable. End-point 
titration relies on the cell-lines used and on the time of 
incubation before staining, both critical parameters that 
have no gold standard. Therefore, although useful within 
a study itself, direct comparison of end-point titration 
values from different sources would provide not much 
more than coarse approximation of infectivity potential. 
In addition, it has been reported on several occasions 
that vector could clearly acquire BTV from animals with 
a lower viraemia, sometimes even undetectable through 
classical isolation techniques [51, 52]. Moreover, viraemia 
levels only make epidemiological sense in the light of the 
considered serotype or strain [45] and vectors biology, i.e. 
biting rates and oral susceptibility, as these parameters 
are species dependent and likewise population depend-
ent [53]. These results also highlight the interest of using 
natural host species; indeed the tested serotypes had in 
VERO cell culture replication properties that did not 
significantly differ whereas in cattle in the current study 
BTV1, 9 and 16 appear to be better adapted to cattle 
than BTV2 and BTV4. In addition, Coetzee et al. recently 
reported the absence of correlation between replication 
levels in VERO cells and virulence in ruminant host [54]. 
Therefore, as useful as could in vitro tests or mice mod-
els be to clarify pathogenicity mechanisms or to allow 
preliminary vaccine evaluations, they are unable to fully 
replace natural host experimental infections, which has 
to be chosen with special emphasis on the specie that 
represent the most relevant economical issue.
Broadly speaking, the results only indicated minor sig-
nificant differences between the vaccinated/non-vacci-
nated groups although some quite obvious differences 
between the different serotype groups. One of the factors 
surely attributing to the non-significant differences is the 
fact the number of animals per group was low thus lim-
iting the power of the statistical analysis. Further study 
focussing on some particular aspects using a higher num-
ber of individuals could clarify some of those points.
Amongst the BTV serotypes evaluated in this study, 
BTV1, BTV9 and BTV16 appeared to be better adapted 
to cattle host than BTV2 and BTV4. None of the tested 
serotypes could cause serious clinical disease. Viral 
RNA copy number was higher at viraemic peak in 
non-vaccinated animals. Viral detection at the virae-
mic peak and in the organs at necropsy suggests a par-
tial and minor protection of BTV8 vaccination against 
infection with European heterologous serotypes in 
an experimental context. The very limited serological 
cross reactivity between the different tested serotypes 
most likely suggests cellular based mechanisms. It has 
been recently reported that West Nile virus lineages 
that induce different mortality rates in the field could 
cause similar mortality in experimental conditions, the 
discrepancy putatively thought to be linked to a differ-
ent host competence among these strains [55]. Vector 
borne viruses are in permanent interaction with envi-
ronment, hosts and vectors; therefore the epidemiolog-
ical meaning of the potential effect of a mass anti-BTV8 
vaccination to (partially) protect cattle livestock from 
heterologous serotypes remains uncertain.
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